<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01919346</url>
  </required_header>
  <id_info>
    <org_study_id>13-0920</org_study_id>
    <nct_id>NCT01919346</nct_id>
  </id_info>
  <brief_title>Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation</brief_title>
  <official_title>Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heeger, Peter, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heeger, Peter, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of Eculizumab in the prevention of&#xD;
      Delayed Graft Function following deceased donor kidney transplantation. Based on experimental&#xD;
      data and supportive observations in humans associating complement gene upregulation with&#xD;
      ischemic reperfusion (IR) injury, it is hypothesized that C5 cleavage is a key step in the&#xD;
      pathogenesis of ischemic reperfusion injury following transplantation. It is further&#xD;
      hypothesized that Eculizumab, a humanized monoclonal antibody that blocks C5 cleavage in&#xD;
      humans will be an effective prophylactic agent to prevent IR injury in high risk recipients.&#xD;
      This trial is a prospective, randomized study to test the efficacy of eculizumab vs. placebo&#xD;
      given once at the time of transplantation and once again 24 hours later in preventing delayed&#xD;
      graft function in first adult recipients of deceased donor kidneys.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on results from Alexion PROTECT DGF study&#xD;
  </why_stopped>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodialysis</measure>
    <time_frame>7 days post-transplantation</time_frame>
    <description>The need of at least one dialysis treatment during the first 7 days after transplantation excluding: (i) requirement for a single dialysis session indicated for hyperkalemia (ii) hyperacute rejection, renal arterial and/or venous thrombosis, obstructive uropathy, recurrence of primary disease, and early thrombotic microangiopathy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated Glomerular Filtration Rate (GFR)</measure>
    <time_frame>6 months post-transplantation</time_frame>
    <description>Estimated GFR as determined from the 4-variable MDRD (Modified Diet in Renal Disease) equation on days 7, 30, 90 and 180 post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodialysis</measure>
    <time_frame>8 weeks post-transplantation</time_frame>
    <description>Number of dialysis sessions at 30 days and 8 weeks post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Non-function</measure>
    <time_frame>8 weeks post-transplantation</time_frame>
    <description>The incidence of primary non-function (PNF) defined as the need for dialysis-dependency for more than 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Rejection</measure>
    <time_frame>6 months post-transplantation</time_frame>
    <description>Incidence of graft rejection within 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Survival</measure>
    <time_frame>12 months post-transplantation</time_frame>
    <description>Patient survival at 12 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Survival</measure>
    <time_frame>12 months post-transplantation</time_frame>
    <description>Death censored graft survival at 12 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>3 days post-transplantation</time_frame>
    <description>Change from baseline in serum creatinine and serum creatinine concentration at 24, 48 and 72 hours post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Output</measure>
    <time_frame>3 days post-transplantation</time_frame>
    <description>Percentage of patients with total 24-hour urine output of more than 500 mL on post-transplantation days 2 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>6 months post-transplantation</time_frame>
    <description>Absolute levels of biomarkers associated with acute renal injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualified Delayed Graft Function (qDGF)</measure>
    <time_frame>7 days post-transplantation</time_frame>
    <description>The incidence of qDGF defined as the requirement for dialysis for any reason in the first 7 days post-transplantation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Delayed Graft Function</condition>
  <condition>Kidney Transplantation</condition>
  <condition>Complement Activity</condition>
  <arm_group>
    <arm_group_label>Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eculizumab 1200 mg (diluted in Sodium Chloride (NaCl) to 5mg/mL, volume = 240 mL) will be given intraoperatively at the time of transplantation prior to reperfusion of the renal allograft and again at 900 mg (diluted in NaCl to 5mg/mL, volume = 180 mL) 12-24 hours post-transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered at same volume and time as Experimental arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <arm_group_label>Eculizumab</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Weight &gt; 40 kg&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Recipient of first deceased donor kidney&#xD;
&#xD;
          -  Able to provide written informed consent&#xD;
&#xD;
          -  Transplant candidate as per site specific guidelines&#xD;
&#xD;
          -  Dialysis dependent renal failure (initiated more than 2 months prior to transplant)&#xD;
&#xD;
          -  Recipients of kidneys defined as:&#xD;
&#xD;
               1. Extended Criteria Donor (ECD) kidney with brain death: Kidney donors 60 years of&#xD;
                  age or older; or donors aged 50-59 years and have two of the following features:&#xD;
                  Hypertension, terminal serum creatinine &gt; 1.5 mg/dL, or death from&#xD;
                  cerebrovascular accident (CVA), OR&#xD;
&#xD;
               2. Standard Criteria Donor (SCD) kidney with actual cold ischemia time (CIT) 18 - 40&#xD;
                  hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is planned to receive a multi-organ transplant&#xD;
&#xD;
          -  Kidney from donor &lt; 6 years of age&#xD;
&#xD;
          -  Dual kidney transplant (from same donor, including en bloc)&#xD;
&#xD;
          -  Living donor kidney transplant&#xD;
&#xD;
          -  Recipients with donor-specific anti-HLA antibodies of more than 3,000 MFI&#xD;
&#xD;
          -  Participation in another investigational drug study&#xD;
&#xD;
          -  Recipient BMI &gt; 40&#xD;
&#xD;
          -  ABO incompatible&#xD;
&#xD;
          -  DCD (donor with cardiac death) Donor&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding&#xD;
&#xD;
          -  Women of child bearing potential who are unable or unwilling to use a medically&#xD;
             acceptable form of contraception (defined as the use of oral, injected or implanted&#xD;
             hormonal methods of contraception, intrauterine device (IUD)or intrauterine system&#xD;
             (IUS), barrier methods of contraception (condom or occlusive cap with spermicidal&#xD;
             foam/gel/film/cream/suppository)&#xD;
&#xD;
          -  Patients with HBsAg-positive status, HCV infection, or HIV infection&#xD;
&#xD;
          -  Patients with atypical hemolytic uremic syndrome (aHUS) or C3 glomerulonephritis&#xD;
             (C3GN)&#xD;
&#xD;
          -  Active bacterial or other infection which is clinically significant in the opinion of&#xD;
             the investigator&#xD;
&#xD;
          -  Patients with history of splenectomy&#xD;
&#xD;
          -  Patients with history of meningococcal disease&#xD;
&#xD;
          -  Patients allergic to or unable to tolerate Ciprofloxacin&#xD;
&#xD;
          -  Patients unable or unwilling to receive vaccination against meningitis prior to study&#xD;
             drug administration&#xD;
&#xD;
          -  Patients with a known or suspected hereditary complement deficiency&#xD;
&#xD;
          -  Patients with a history of cancer (other than non melanoma skin cancers) within the&#xD;
             last five years&#xD;
&#xD;
          -  Donors of more than 70 years of age&#xD;
&#xD;
          -  Subjects with a psychiatric or physical illness which in the opinion of the&#xD;
             Investigator would interfere with their ability to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter S Heeger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale - New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>August 7, 2013</study_first_submitted>
  <study_first_submitted_qc>August 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2013</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Delayed Graft Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delayed Graft Function</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eculizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

